Weight and height in children newly diagnosed with cancer

Aeltsje Brinksma1,2, Petrie F Roodbol1, Esther Sulkers1,2

  • 1School of Nursing and Health, University of Groningen, University Medical Center Groningen, The Netherlands.

Pediatric Blood & Cancer
|November 1, 2014
PubMed

Insights

Pediatric cancer patients often experience weight loss and growth issues. This study found nearly 25% of newly diagnosed children had reduced weight-for-age, height-for-age, and weight-for-height z-scores, indicating poor nutritional status.

Area of Science:

  • Pediatric Oncology
  • Nutritional Science
  • Growth Monitoring

Background:

  • Growth history is often overlooked in nutritional status research for pediatric cancer patients.
  • Children with cancer frequently experience weight loss and impaired linear growth.

Purpose of the Study:

  • To determine the prevalence of weight loss and lack of linear growth in children newly diagnosed with cancer.
  • To assess if growth history data is crucial for evaluating nutritional status in this population.

Main Methods:

  • Recorded weight and height in 95 children (1.5-10 years) at diagnosis.
  • Compared actual measurements to predicted data from growth curves.
  • Analyzed factors like age, gender, cancer type, and disease extent.

Main Results:

  • 25% of children exhibited significant reductions in weight-for-age, height-for-age, and weight-for-height z-scores.
  • Children with advanced cancer had a higher risk of significant weight loss before diagnosis.
  • Undernutrition incidence was 2% (weight-for-age), 4% (height-for-age), and 7% (weight-for-height).

Conclusions:

  • A significant proportion of newly diagnosed pediatric cancer patients present with deteriorated nutritional status.
  • Incorporating growth history assessment into standard care is vital for timely nutritional interventions.
  • Growth assessment should be a standard component of research evaluating nutritional status in pediatric cancer.
Abstract

Related Concept Videos

Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
972
Nature and Nurture01:10

Nature and Nurture

Many human characteristics, like height, are shaped by both nature—in other words, by our genes—and by nurture, or our environment. For example, chronic stress during childhood inhibits the production of growth hormones and consequently reduces bone growth and height. Scientists estimate that 70-90% of variation in height is due to genetic differences among individuals, and 10-30% of variation in height is due to differences in the environments that individuals experience,...
19.3K
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
353
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
532
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
395
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
918